The discovery of antibiotics has trailed substantially behind the emergence of resistant species. Only 8 new
antibiotics were authorised by the US Food and Drug Administration between 2010 and 2015. Seven have
comparable modes of action to medicines that are presently on the market. However, historical experience with
antibiotics such as linezolid, levofloxacin, and ceftaroline should temper optimism as resistant organisms to each
of these medications arose within a year or less following their introduction.